Stock Events

Stock Events

Regen Biopharma 

$0
10
+$0+40.7% Today

Statistics

Day High
0
Day Low
0
52W High
0.1
52W Low
0
Volume
48
Avg. Volume
406,011
Mkt Cap
362,513.2
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

15NovExpected
Q3 2020
Q4 2020
Q2 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.01
-0
0
0.01
Expected EPS
N/A
Actual EPS
0

Financials

-537.97%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
474,000Revenue
-2.55MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGBPP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the innovative biotech space focusing on genetic diseases, similar to Regen Biopharma's focus on gene silencing and modulation.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing field, directly competing with Regen Biopharma's gene therapy and modulation technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading developer of CRISPR gene editing treatments, competing in the same space as Regen Biopharma's gene-based therapies.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing directly with Regen Biopharma's focus on gene modulation for treating diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapies, competing in the same space as Regen Biopharma's focus on gene silencing technologies.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics works on base editing, a form of gene editing, presenting direct competition to Regen Biopharma's gene modulation efforts.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing in the broader biotech space alongside Regen Biopharma.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is known for its work in treating genetic diseases, directly competing with Regen Biopharma's focus on gene therapies.

About

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
Show more...
CEO
Dr. David Raymond Koos DBA, Ph.D.
Employees
1
Country
US
ISIN
US75886M4096

Listings

OTC Link
US
RGBP
OTC Link
US
RGBPP

0 Comments

Share your thoughts

FAQ

What is Regen Biopharma stock price today?▼
The current price of RGBPP is $0 USD — it has increased by +40.7% in the past 24 hours. Watch Regen Biopharma stock price performance more closely on the chart.
What is Regen Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Regen Biopharma stocks are traded under the ticker RGBPP.
Is Regen Biopharma stock price growing?▼
RGBPP stock has fallen by -12.5% compared to the previous week, the month change is a -22.22% fall, over the last year Regen Biopharma has showed a -90.74% decrease.
What is Regen Biopharma market cap?▼
Today Regen Biopharma has the market capitalization of 362,513.2
What were Regen Biopharma earnings last quarter?▼
RGBPP earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regen Biopharma revenue for the last year?▼
Regen Biopharma revenue for the last year amounts to 474,000 USD.
What is Regen Biopharma net income for the last year?▼
RGBPP net income for the last year is -2.55M USD.
How many employees does Regen Biopharma have?▼
As of April 01, 2026, the company has 1 employees.
In which sector is Regen Biopharma located?▼
Regen Biopharma operates in the Health Care sector.
When did Regen Biopharma complete a stock split?▼
The last stock split for Regen Biopharma was on February 03, 2026 with a ratio of 2:1.
Where is Regen Biopharma headquartered?▼
Regen Biopharma is headquartered in La Mesa, US.